Clinical Trial

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Name: Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors — clinical trial record (NCT07517198)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-04-03.

Trial Details

NCT Number	NCT07517198
Lead Sponsor	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Conditions	Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell) +4 more
Enrollment	40 participants
Start Date	2026-04-13
Primary Completion	2029-03 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-10